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The medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data
on the benefits and risks of these therapies and procedures
can improve the quality of care, optimize patient outcomes,
and favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to
a thorough review of evidence has resulted in the production
of clinical practice guidelines that assist physicians in se-
lecting the best management strategy for an individual pa-
tient. Moreover, clinical practice guidelines can provide
a foundation for other applications, such as performance
measures, appropriate use criteria, and both quality im-
provement and clinical decision support tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
jointly produced guidelines in the area of cardiovascular
disease since 1980. The ACCF/AHATask Force on Practice
Guidelines (Task Force), charged with developing, updat-
ing, and revising practice guidelines for cardiovascular dis-
eases and procedures, directs and oversees this effort.
Writing committees are charged with regularly reviewing
and evaluating all available evidence to develop balanced,
patient-centric recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-specific data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a formal literature review;Cardiovascular Surgery c Volume 143, Number 1 5
TABLE 1. Applying classification of recommendations and level of evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data
available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction,
history of heart failure, and prior aspirin use. yFor comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of
comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
Clinical Guideline Hillis et alweigh the strength of evidence for or against particular tests,
treatments, or procedures; and include estimates of ex-
pected outcomes where such data exist. Patient-specific
modifiers, comorbidities, and issues of patient preference
that may influence the choice of tests or therapies are con-
sidered. When available, information from studies on cost
is considered, but data on efficacy and outcomes constitute
the primary basis for the recommendations contained
herein.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force.1 The
Class of Recommendation (COR) is an estimate of the6 The Journal of Thoracic and Cardiovascular Surgersize of the treatment effect considering risks versus benefits
in addition to evidence and/or agreement that a given
treatment or procedure is or is not useful/effective or in
some situations may cause harm. The Level of Evidence
(LOE) is an estimate of the certainty or precision of the
treatment effect. The writing committee reviews and ranks
evidence supporting each recommendation with the weight
of evidence ranked as LOE A, B, or C according to specific
definitions that are included in Table 1. Studies are identi-
fied as observational, retrospective, prospective, or random-
ized where appropriate. For certain conditions for which
inadequate data are available, recommendations are based
on expert consensus and clinical experience and are rankedy c January 2012
Hillis et al Clinical Guidelineas LOE C. When recommendations at LOE C are supported
by historical clinical data, appropriate references (including
clinical reviews) are cited if available. For issues for which
sparse data are available, a survey of current practice among
the clinicians on the writing committee is the basis for LOE
C recommendations, and no references are cited. The
schema for COR and LOE is summarized in Table 1, which
also provides suggested phrases for writing recommenda-
tions within each COR. A new addition to this methodology
is separation of the Class III recommendations to delineate
if the recommendation is determined to be of ‘‘no benefit’’
or is associated with ‘‘harm’’ to the patient. In addition, in
view of the increasing number of comparative effectiveness
studies, comparator verbs and suggested phrases for writing
recommendations for the comparative effectiveness of one
treatment or strategy versus another have been added for
COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across
the spectrum of cardiovascular diseases, the Task Force
has designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as defined by
ACCF/AHA guideline-recommended therapies (primarily
Class I). This new term, GDMT, will be used herein and
throughout all future guidelines.
Because the ACCF/AHA practice guidelines address pa-
tient populations (and healthcare providers) residing in
North America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing committee reviews
the potential influence of different practice patterns and pa-
tient populations on the treatment effect and relevance to
the ACCF/AHA target population to determine whether
the findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to
assist healthcare providers in clinical decision making
by describing a range of generally acceptable approaches
to the diagnosis, management, and prevention of specific
diseases or conditions. The guidelines attempt to define
practices that meet the needs of most patients in most
circumstances. The ultimate judgment regarding the care
of a particular patient must be made by the healthcare pro-
vider and patient in light of all the circumstances pre-
sented by that patient. As a result, situations may arise
for which deviations from these guidelines may be appro-
priate. Clinical decision making should involve consider-
ation of the quality and availability of expertise in the area
where care is provided. When these guidelines are used as
the basis for regulatory or payer decisions, the goal should
be improvement in quality of care. The Task Force recog-
nizes that situations arise in which additional data are
needed to inform patient care more effectively; these areas
will be identified within each respective guideline when
appropriate.The Journal of Thoracic andPrescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because
lack of patient understanding and adherence may adversely
affect outcomes, physicians and other healthcare providers
should make every effort to engage the patient’s active par-
ticipation in prescribed medical regimens and lifestyles. In
addition, patients should be informed of the risks, benefits,
and alternatives to a particular treatment and be involved in
shared decision making whenever feasible, particularly for
COR IIa and IIb, where the benefit-to-risk ratio may be
lower.
The Task Force makes every effort to avoid actual, poten-
tial, or perceived conflicts of interest that may arise as a re-
sult of industry relationships or personal interests among the
members of the writing committee. All writing committee
members and peer reviewers of the guideline are required
to disclose all such current relationships, as well as those ex-
isting 12 months previously. In December 2009, the ACCF
and AHA implemented a new policy for relationships with
industry and other entities (RWI) that requires the writing
committee chair plus a minimum of 50% of the writing
committee to have no relevant RWI (Appendix 1 for the
ACCF/AHA definition of relevance). These statements are
reviewed by the Task Force and all members during each
conference call and meeting of the writing committee and
are updated as changes occur. All guideline recommenda-
tions require a confidential vote by the writing committee
and must be approved by a consensus of the voting mem-
bers. Members are not permitted to write, and must rescue
themselves from voting on, any recommendation or section
to which their RWI apply. Members who recused them-
selves from voting are indicated in the list of writing
committee members, and section recusals are noted in
Appendix 1. Authors’ and peer reviewers’ RWI pertinent to
this guideline are disclosed in Appendixes 1 and 2, respec-
tively. Additionally, to ensure complete transparency, writing
committee members’ comprehensive disclosure informa-
tion—including RWI not pertinent to this document—is
available as an online supplement. Comprehensive disclosure
information for the Task Force is also available online at
www.cardiosource.org/ACC/About-ACC/Leadership/Guide
lines-and-Documents-Task-Forces.aspx. The work of the
writing committee was supported exclusively by the ACCF
and AHA without commercial support. Writing committee
members volunteered their time for this activity.
In an effort to maintain relevance at the point of care for
practicing physicians, the Task Force continues to oversee
an ongoing process improvement initiative. As a result, in
response to pilot projects, evidence tables (with references
linked to abstracts in PubMed) have been added.
In April 2011, the Institute of Medicine released 2 re-
ports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We
Can Trust.2,3 It is noteworthy that the ACCF/AHACardiovascular Surgery c Volume 143, Number 1 7
Clinical Guideline Hillis et alguidelines are cited as being compliant with many of the
proposed standards. A thorough review of these reports
and of our current methodology is under way, with further
enhancements anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update or
the full-text guideline is revised. Guidelines are official pol-
icy of both the ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines1. INTRODUCTION
1.1. Methodology and Evidence Review
Whenever possible, the recommendations listed in this
document are evidence based. Articles reviewed in this
guideline revision covered evidence from the past 10 years
through January 2011, as well as selected other references
through April 2011. Searches were limited to studies, re-
views, and evidence conducted in human subjects that
were published in English. Key search words included but
were not limited to: analgesia, anastomotic techniques,
antiplatelet agents, automated proximal clampless anasto-
mosis device, asymptomatic ischemia, Cardica C-port,
cost effectiveness, depressed left ventricular (LV) function,
distal anastomotic techniques, direct proximal anastomosis
on aorta, distal anastomotic devices, emergency coronary
artery bypass graft (CABG) and ST-elevation myocardial
infarction (STEMI), heart failure, interrupted sutures, LV
systolic dysfunction, magnetic connectors, PAS-Port auto-
mated proximal clampless anastomotic device, patency,
proximal connectors, renal disease, sequential anastomosis,
sternotomy, symmetry connector, symptomatic ischemia,
proximal connectors, sequential anastomosis, T grafts, tho-
racotomy, U-clips, Ventrica Magnetic Vascular Port system,
Y grafts. Additionally, the committee reviewed documents
related to the subject matter previously published by the
ACCF and AHA. References selected and published in
this document are representative but not all-inclusive.
The guideline is focused on the safe, appropriate, and ef-
ficacious performance of CABG. The STEMI, percutane-
ous coronary intervention (PCI), and CABG guidelines
were written concurrently, with additional collaboration
from the Stable Ischemic Heart Disease (SIHD) guideline
writing committee. This allowed greater collaboration
among the different writing committees on topics such as
PCI in STEMI and revascularization strategies in patients
with coronary artery disease (CAD) (including unprotected
left main PCI, multivessel disease revascularization, and
hybrid procedures).
In accordance with the direction of the Task Force and
feedback from readers, in this iteration of the guideline,
the amount of text has been shortened, and emphasis has
been placed on summary statements rather than detailed8 The Journal of Thoracic and Cardiovascular Surgerdiscussion of numerous individual trials. Online supple-
mental evidence and summary tables have been created to
document the studies and data considered for new or
changed guideline recommendations.
Because the executive summary contains only the recom-
mendations, the reader is encouraged to consult the full-text
guideline4 for additional detail on the recommendations and
guidance on the care of the patient undergoing CABG.1.2. Organization of the Writing Committee
The committee was composed of acknowledged experts
in CABG, interventional cardiology, general cardiology,
and cardiovascular anesthesiology. The committee included
representatives from the ACCF, AHA, American Associa-
tion for Thoracic Surgery, Society of Cardiovascular Anes-
thesiologists, and Society of Thoracic Surgeons (STS).1.3. Document Review and Approval
This document was reviewed by 2 official reviewers, each
nominated by both the ACCF and the AHA, as well as 1 re-
viewer each from the American Association for Thoracic
Surgery, Society of Cardiovascular Anesthesiologists, and
STS, as well as members from the ACCF/AHATask Force
on Data Standards, ACCF/AHATask Force on Performance
Measures, ACCF Surgeons’ Scientific Council, ACCF
Interventional Scientific Council, and Southern Thoracic
Surgical Association. All information on reviewers’ RWIs
was distributed to the writing committee and is published
in this document (Appendix 2. This document was ap-
proved for publication by the governing bodies of the
ACCF and the AHA and endorsed by the American Associ-
ation for Thoracic Surgery, Society of Cardiovascular
Anesthesiologists, and STS.2. PROCEDURAL CONSIDERATIONS:
RECOMMENDATIONS
2.1. Anesthetic Considerations
Class I
1. Anesthetic management directed toward early postoperative extu-
bation and accelerated recovery of low- to medium-risk patients
undergoing uncomplicated CABG is recommended.5-7 (Level of
Evidence: B)
2. Multidisciplinary efforts are indicated to ensure an optimal level of
analgesia and patient comfort throughout the perioperative pe-
riod.8-12 (Level of Evidence: B)
3. Efforts are recommended to improve interdisciplinary communica-
tion and patient safety in the perioperative environment (eg, formal-
ized checklist-guided multidisciplinary communication).13-16 (Level
of Evidence: B)
4. A fellowship-trained cardiac anesthesiologist (or experienced
board-certified practitioner) credentialed in the use of periopera-
tive transesophageal echocardiography is recommended to provide
or supervise anesthetic care of patients who are considered to be at
high risk.17-19 (Level of Evidence: C)y c January 2012
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1. Volatile anesthestic-based regimens can be useful in facilitating early
extubation and reducing patient recall.6,20-22 (Level of Evidence: A)
Class IIb
1. The effectiveness of high thoracic epidural anesthesia/analgesia for
routine analgesic use is uncertain.23-26 (Level of Evidence: B)
Class III: Harm
1. Cyclooxygenase-2 inhibitors are not recommended for pain relief in
the postoperative period after CABG.27,28 (Level of Evidence: B)
2. Routine use of early extubation strategies in facilities with limited
backup for airway emergencies or advanced respiratory support
is potentially harmful. (Level of Evidence: C)2.2. Bypass Graft Conduit
Class I
1. If possible, the left internal mammary artery (LIMA) should be
used to bypass the left anterior descending (LAD) artery when
bypass of the LAD artery is indicated.29-32 (Level of Evidence: B)
Class IIa
1. The right internal mammary artery is probably indicated to bypass
the LAD artery when the LIMA is unavailable or unsuitable as
a bypass conduit. (Level of Evidence: C)
2. When anatomically and clinically suitable, use of a second internal
mammary artery to graft the left circumflex or right coronary
artery (when critically stenosed and perfusing LV myocardium) is
reasonable to improve the likelihood of survival and to decrease
reintervention.33-37 (Level of Evidence: B)
Class IIb
1. Complete arterial revascularization may be reasonable in patients
less than or equal to 60 years of age with few or no comorbidities.
(Level of Evidence: C)
2. Arterial grafting of the right coronary artery may be reasonable
when a critical (90%) stenosis is present.32,36,38 (Level of
Evidence: B)
3. Use of a radial artery graft may be reasonable when grafting
left-sided coronary arteries with severe stenoses (>70%) and
right-sided arteries with critical stenoses (90%) that perfuse LV
myocardium.39-44 (Level of Evidence: B)
Class III: Harm
1. An arterial graft should not be used to bypass the right coronary ar-
terywith less than a critical stenosis (<90%).32 (Level ofEvidence:C)2.3. Intraoperative Transesophageal
Echocardiography
Class I
1. Intraoperative transesophageal echocardiography should be
performed for evaluation of acute, persistent, and life-threatening
hemodynamic disturbances that have not responded to treat-
ment.45,46 (Level of Evidence: B)The Journal of Thoracic and2. Intraoperative transesophageal echocardiography should be per-
formed in patients undergoing concomitant valvular surgery.45,47
(Level of Evidence: B)
Class IIa
1. Intraoperative transesophageal echocardiography is reasonable for
monitoring of hemodynamic status, ventricular function, regional
wall motion, and valvular function in patients undergoing
CABG.46,48-53 (Level of Evidence: B)2.4. Preconditioning/Management of Myocardial
Ischemia
Class I
1. Management targeted at optimizing the determinants of coronary
arterial perfusion (eg, heart rate, diastolic or mean arterial pres-
sure, and right ventricular or LV end-diastolic pressure) is recom-
mended to reduce the risk of perioperative myocardial ischemia
and infarction.54-58 (Level of Evidence: B)
Class IIa
1. Volatile-based anesthesia can be useful in reducing the risk of perio-
perativemyocardial ischemia and infarction.59-62 (Level of Evidence:
A)
Class IIb
1. The effectiveness of prophylactic pharmacological therapies or
controlled reperfusion strategies aimed at inducing precondition-
ing or attenuating the adverse consequences of myocardial reperfu-
sion injury or surgically induced systemic inflammation is
uncertain.63-70 (Level of Evidence: A)
2. Mechanical preconditioning might be considered to reduce the risk
of perioperative myocardial ischemia and infarction in patients un-
dergoing off-pump CABG.71-73 (Level of Evidence: B)
3. Remote ischemic preconditioning strategies using peripheral-
extremity occlusion/reperfusion might be considered to attenuate
the adverse consequences of myocardial reperfusion injury.74-76
(Level of Evidence: B)
4. The effectiveness of postconditioning strategies to attenuate the ad-
verse consequences of myocardial reperfusion injury is uncer-
tain.77,78 (Level of Evidence: C)2.5. Clinical Subsets
2.5.1. CABG in Patients With Acute Myocardial
Infarction
Class I
1. Emergency CABG is recommended in patients with acute myocar-
dial infarction (MI) in whom (1) primary PCI has failed or cannot
be performed, (2) coronary anatomy is suitable for CABG, and (3)
persistent ischemia of a significant area of myocardium at rest and/
or hemodynamic instability refractory to nonsurgical therapy is
present.79-83 (Level of Evidence: B)
2. Emergency CABG is recommended in patients undergoing surgical
repair of a postinfarction mechanical complication of MI, such as
ventricular septal rupture,mitral valve insufficiencybecause of pap-
illary muscle infarction and/or rupture, or free wall rupture.84-88
(Level of Evidence: B)Cardiovascular Surgery c Volume 143, Number 1 9
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shock and who are suitable for CABG irrespective of the time
interval from MI to onset of shock and time from MI to
CABG.82,89-91 (Level of Evidence: B)
4. EmergencyCABG is recommended in patients with life-threatening
ventricular arrhythmias (believed to be ischemic in origin) in the
presence of left main stenosis greater than or equal to 50% and/
or 3-vessel CAD.92 (Level of Evidence: C)
Class IIa
1. The use of CABG is reasonable as a revascularization strategy in
patients with multivessel CAD with recurrent angina or MI
within the first 48 hours of STEMI presentation as an alternative
to a more delayed strategy.79,81,83,93 (Level of Evidence: B)
2. Early revascularization with PCI or CABG is reasonable for selected
patients greater than 75 years of age with ST-segment elevation or
left bundle branch block who are suitable for revascularization irre-
spective of the time interval from MI to onset of shock.94-98 (Level of
Evidence: B)
Class III: Harm
1. Emergency CABG should not be performed in patients with persis-
tent angina and a small area of viable myocardium who are stable
hemodynamically. (Level of Evidence: C)
2. Emergency CABG should not be performed in patients with no-
reflow (successful epicardial reperfusion with unsuccessful micro-
vascular reperfusion). (Level of Evidence: C)
2.5.2. Life-Threatening Ventricular Arrhythmias
Class I
1. CABG is recommended in patientswith resuscitated sudden cardiac
death or sustained ventricular tachycardia thought to be caused by
significant CAD (50% stenosis of left main coronary artery and/or
70% stenosis of 1, 2, or all 3 epicardial coronary arteries) and
resultant myocardial ischemia.92,99,100 (Level of Evidence: B)
Class III: Harm
1. CABG should not be performed in patients with ventricular tachy-
cardia with scar and no evidence of ischemia. (Level of Evidence: C)
2.5.3. Emergency CABG After Failed PCI
Class I
1. Emergency CABG is recommended after failed PCI in the presence
of ongoing ischemia or threatened occlusion with substantial myo-
cardium at risk.101,102 (Level of Evidence: B)
2. Emergency CABG is recommended after failed PCI for hemody-
namic compromise in patients without impairment of the coagu-
lation system and without a previous sternotomy.101,103,104 (Level
of Evidence: B)
Class IIa
1. Emergency CABG is reasonable after failed PCI for retrieval of
a foreign body (most likely a fractured guidewire or stent) in a cru-
cial anatomic location. (Level of Evidence: C)
2. Emergency CABG can be beneficial after failed PCI for hemody-
namic compromise in patients with impairment of the coagulation
system and without previous sternotomy. (Level of Evidence: C)10 The Journal of Thoracic and Cardiovascular SurgeClass IIb
1. Emergency CABG might be considered after failed PCI for hemo-
dynamic compromise in patients with previous sternotomy. (Level
of Evidence: C)
Class III: Harm
1. Emergency CABG should not be performed after failed PCI in the
absence of ischemia or threatened occlusion. (Level of Evidence: C)
2. Emergency CABG should not be performed after failed PCI if
revascularization is impossible because of target anatomy or
a no-reflow state. (Level of Evidence: C)2.5.4. CABG in Association With Other Cardiac
Procedures
Class I
1. CABG is recommended in patients undergoing noncoronary car-
diac surgery with greater than or equal to 50% luminal diameter
narrowing of the left main coronary artery or greater than or equal
to 70% luminal diameter narrowing of other major coronary
arteries. (Level of Evidence: C)Class IIa
1. The use of the LIMA is reasonable to bypass a significantly nar-
rowed LAD artery in patients undergoing noncoronary cardiac sur-
gery. (Level of Evidence: C)
2. CABG of moderately diseased coronary arteries (>50% luminal
diameter narrowing) is reasonable in patients undergoing noncoro-
nary cardiac surgery. (Level of Evidence: C)3. CAD REVASCULARIZATION:
RECOMMENDATIONS
Recommendations and text in this section are the result of
extensive collaborative discussions between the PCI and
CABG writing committees as well as key members of the
SIHD and Unstable Angina/Non-ST-Elevation Myocardial
Infarction (UA/NSTEMI) writing committees. Certain is-
sues, such as older versus more contemporary studies, pri-
mary analyses versus subgroup analyses, and prospective
versus post hoc analyses, have been carefully weighed in
designating COR and LOE; they are addressed in the appro-
priate corresponding text.4
The goals of revascularization for patients with CAD are
to (1) to improve survival and (2) to relieve symptoms. The
following text contains recommendations for revasculariza-
tion toimprove survival and symptoms. These recommen-
dations are summarized in Tables 2 and 3.
Revascularization recommendations in this section are
predominantly based on studies of patients with symptom-
atic SIHD and should be interpreted in this context. As dis-
cussed later in this section, recommendations on the type of
revascularization are, in general, applicable to patients with
UA/NSTEMI. In some cases (eg, unprotected left mainry c January 2012
TABLE 2. Revascularization to improve survival compared with medical therapy
CABG, Coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD,
left anterior descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous coronary intervention; SIHD,
stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between percutaneous coronary intervention
with TAXUS and cardiac surgery; TIMI, Thrombolysis In Myocardial Infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction;UPLM, unprotected left
main; VT, ventricular tachycardia. *In patients with multivessel diseasewho also have diabetes, it is reasonable to choose CABG (with LIMA) over PCI155,168-175 (Class IIa/LOE: B).
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TABLE 3. Revascularization to improve symptoms with significant anatomic (50% left main or 70% non–left main CAD) or physiological
(FFR0.80) coronary artery stenoses
CABG, Coronary artery bypass graft; CAD, coronary artery disease; COR, class of recommendation; FFR, fractional flow reserve; GDMT, guideline-directed medical therapy;
LOE, level of evidence; N/A, not applicable; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac
Surgery; TMR, transmyocardial laser revascularization.
Clinical Guideline Hillis et alCAD), specific recommendations are made for patients with
UA/NSTEMI or STEMI.
3.1. Heart Team Approach to Revascularization
Decisions
Class I
1. A Heart Team approach to revascularization is recommended in
patients with unprotected left main or complex CAD.105-107 (Level of
Evidence: C)
Class IIa
1. Calculation of the STS and SYNTAX (Synergy between Percutane-
ous Coronary Intervention with TAXUS and Cardiac Surgery)
scores is reasonable in patients with unprotected left main and
complex CAD.107-114 (Level of Evidence: B)3.2. Revascularization to Improve Survival
Left Main CAD Revascularization
Class I
1. CABG to improve survival is recommended for patients with
significant (50% diameter stenosis) left main coronary artery
stenosis.115-121 (Level of Evidence: B)
Class IIa
1. PCI to improve survival is reasonable as an alternative to CABG
in selected stable patients with significant (50% diameter steno-
sis) unprotected left main CAD with: (1) anatomic conditions asso-
ciated with a low risk of PCI procedural complications and a high
likelihood of good long-term outcome eg, a low SYNTAX score
[22], ostial or trunk left main CAD); and (2) clinical character-
istics that predict a significantly increased risk of adverse surgical
outcomes (eg, STS-predicted risk of operative mortality
5%).108,110,111,122-140,168 (Level of Evidence: B)
2. PCI to improve survival is reasonable in patients with UA/
NSTEMI when an unprotected left main coronary artery is12 The Journal of Thoracic and Cardiovascular Surgethe culprit lesion and the patient is not a candidate for
CABG.111,127,129-131,136,137,139,140,142 (Level of Evidence: B)
3. PCI to improve survival is reasonable in patients with acute STEMI
when an unprotected left main coronary artery is the culprit lesion,
distal coronary flow is less thanThrombolysis InMyocardial Infarc-
tion grade 3, and PCI can be performed more rapidly and safely
than CABG.124,143,144 (Level of Evidence: C)
Class IIb
1. PCI to improve survival may be reasonable as an alternative to
CABG in selected stable patients with significant (50% diameter
stenosis) unprotected left main CAD with: (1) anatomic conditions
associated with a low to intermediate risk of PCI procedural com-
plications and an intermediate to high likelihood of good long-
term outcome (eg, low-intermediate SYNTAX score of<33, bifurca-
tion left main CAD); and (2) clinical characteristics that predict an
increased risk of adverse surgical outcomes (eg, moderate-severe
chronic obstructive pulmonary disease, disability from previous
stroke, or previous cardiac surgery; STS-predicted risk of operative
mortality>2%).108,110,111,122-140,145 (Level of Evidence: B)
Class III: Harm
1. PCI to improve survival should not be performed in stable patients
with significant (50% diameter stenosis) unprotected left main
CADwho have unfavorable anatomy for PCI andwho are good can-
didates for CABG.108,110,111,115-123 (Level of Evidence: B)
Non-Left Main CAD Revascularization
Class I
1. CABG to improve survival is beneficial in patients with significant
(70% diameter) stenoses in 3major coronary arteries (with orwith-
out involvement of the proximal LAD artery) or in the proximal LAD
plus 1 othermajor coronary artery.117,121,146-149 (Level ofEvidence: B)
2. CABG or PCI to improve survival is beneficial in survivors of
sudden cardiac death with presumed ischemia-mediated ventricu-
lar tachycardia caused by significant (70% diameter) stenosis in
a major coronary artery. (CABG Level of Evidence: B;99,150,152
PCI Level of Evidence: C150)ry c January 2012
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1. CABG to improve survival is reasonable in patients with significant
(70% diameter) stenoses in 2 major coronary arteries with severe
or extensive myocardial ischemia (eg, high-risk criteria on stress
testing, abnormal intracoronary hemodynamic evaluation, or
>20% perfusion defect by myocardial perfusion stress imaging) or
target vessels supplying a large area of viable myocardium.153-156
(Level of Evidence: B)
2. CABG to improve survival is reasonable in patients with mild-
moderate LV systolic dysfunction (ejection fraction 35% to 50%)
and significant (70% diameter stenosis) multivessel CAD or prox-
imal LAD coronary artery stenosis, when viable myocardium is
present in the region of intended revascularization.121,157-161
(Level of Evidence: B)
3. CABG with a LIMA graft to improve survival is reasonable in pa-
tients with significant (70% diameter) stenosis in the proximal
LAD artery and evidence of extensive ischemia.30,31,121,148 (Level
of Evidence: B)
4. It is reasonable to choose CABG over PCI to improve survival in
patients with complex 3-vessel CAD (eg, SYNTAX score >22),
with or without involvement of the proximal LAD artery, who are
good candidates for CABG.123,138,148,164-165 (Level of Evidence: B)
5. CABG is probably recommended in preference to PCI to improve
survival in patients with multivessel CAD and diabetes mellitus,
particularly if a LIMA graft can be anastomosed to the LAD
artery.155,168-175 (Level of Evidence: B)
Class IIb
1. The usefulness of CABG to improve survival is uncertain in
patients with significant (70%) stenoses in 2 major coronary
arteries not involving the proximal LAD artery and without exten-
sive ischemia.148 (Level of Evidence: C)
2. The usefulness of PCI to improve survival is uncertain in patients
with 2- or 3-vessel CAD (with or without involvement of the proxi-
mal LAD artery) or 1-vessel proximal LAD disease.117,146,148,176
(Level of Evidence: B)
3. CABG might be considered with the primary or sole intent of
improving survival in patients with SIHD with severe LV systolic
dysfunction (ejection fraction<35%) whether or not viablemyocar-
dium is present.121,157-161,177,178 (Level of Evidence: B)
4. The usefulness of CABG or PCI to improve survival is uncertain in
patients with previous CABG and extensive anterior wall ischemia
on noninvasive testing.179-187 (Level of Evidence: B)
Class III: Harm
1. CABG or PCI should not be performed with the primary or sole in-
tent to improve survival in patients with SIHD with 1 or more cor-
onary stenoses that are not anatomically or functionally significant
(eg,<70% diameter non-left main coronary artery stenosis, frac-
tional flow reserve>0.80, no or only mild ischemia on noninvasive
testing), involve only the left circumflex or right coronary artery, or
subtend only a small area of viable myocardium.121,146,153,154,188-192
(Level of Evidence: B)3.3. Revascularization to Improve Symptoms
Class I
1. CABG or PCI to improve symptoms is beneficial in patients with 1
ormore significant (70% diameter) coronary artery stenoses ame-
nable to revascularization and unacceptable angina despite
GDMT.176,193-202 (Level of Evidence: A)The Journal of Thoracic and CClass IIa
1. CABG or PCI to improve symptoms is reasonable in patients with 1
or more significant (70% diameter) coronary artery stenoses and
unacceptable angina for whom GDMT cannot be implemented be-
cause of medication contraindications, adverse effects, or patient
preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous
CABG, 1 or more significant (70% diameter) coronary artery ste-
noses associated with ischemia, and unacceptable angina despite
GDMT.180,183,186 (Level of Evidence: C)
3. It is reasonable to choose CABG over PCI to improve symptoms
in patients with complex 3-vessel CAD (eg, SYNTAX score>22),
with or without involvement of the proximal LAD artery, who
are good candidates for CABG.123,138,148,164-165 (Level of
Evidence: B)
Class IIb
1. CABG to improve symptoms might be reasonable for patients with
previous CABG, 1 or more significant (70% diameter) coronary
artery stenoses not amenable to PCI, and unacceptable angina de-
spite GDMT.187 (Level of Evidence: C)
2. Transmyocardial laser revascularization performed as an adjunct
to CABG to improve symptoms may be reasonable in patients
with viable ischemic myocardium that is perfused by arteries that
are not amenable to grafting.203-207 (Level of Evidence: B)
Class III: Harm
1. CABG or PCI to improve symptoms should not be performed in
patients who do not meet anatomic (50% left main or 70%
non-left main stenosis) or physiological (eg, abnormal fractional
flow reserve) criteria for revascularization. (Level of Evidence: C)3.4. Clinical Factors That May Influence the Choice
of Revascularization
3.4.1. Dual Antiplatelet Therapy Compliance and Stent
Thrombosis
Class III: Harm
1. PCI with coronary stenting (bare-metal stent or drug-eluting stent)
should not be performed if the patient is not likely to be able to tol-
erate and comply with dual antiplatelet therapy for the appropriate
duration of treatment based on the type of stent implanted.208-211
(Level of Evidence: B)3.5. Hybrid Coronary Revascularization
Class IIa
1. Hybrid coronary revascularization (defined as the planned combi-
nation of LIMA-to-LAD artery grafting and PCI of 1 non-LAD
coronary arteries) is reasonable in patients with 1 or more of the
following.212-220 (Level of Evidence: B):
a. Limitations to traditional CABG, such as heavily calcified prox-
imal aorta or poor target vessels for CABG (but amenable to
PCI);
b. Lack of suitable graft conduits;
c. Unfavorable LAD artery for PCI (ie, excessive vessel tortuosity
or chronic total occlusion).ardiovascular Surgery c Volume 143, Number 1 13
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1. Hybrid coronary revascularization (defined as the planned combi-
nation of LIMA-to-LAD artery grafting and PCI of 1 non-LAD
coronary arteries) may be reasonable as an alternative to multives-
sel PCI or CABG in an attempt to improve the overall risk-benefit
ratio of the procedures. (Level of Evidence: C)4. PERIOPERATIVE MANAGEMENT:
RECOMMENDATIONS
4.1. Preoperative Antiplatelet Therapy
Class I
1. Aspirin (100 mg to 325 mg daily) should be administered to CABG
patients preoperatively.221-223 (Level of Evidence: B)
2. In patients referred for elective CABG, clopidogrel and ticagrelor
should be discontinued for at least 5 days before surgery224-226
(Level of Evidence: B) and prasugrel for at least 7 days (Level of
Evidence: C) to limit blood transfusions.
3. In patients referred for urgent CABG, clopidogrel and ticagrelor
should be discontinued for at least 24 hours to reduce major bleed-
ing complications.225,227-229 (Level of Evidence: B)
4. In patients referred for CABG, short-acting intravenous glycopro-
tein IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discon-
tinued for at least 2 to 4 hours before surgery230,231 and
abciximab for at least 12 hours beforehand232 to limit blood loss
and transfusions. (Level of Evidence: B)
Class IIb
1. In patients referred for urgent CABG, it may be reasonable to
perform surgery less than 5 days after clopidogrel or ticagrelor
has been discontinued and less than 7 days after prasugrel has
been discontinued. (Level of Evidence: C)4.2. Postoperative Antiplatelet Therapy
Class I
1. If aspirin (100mg to 325mgdaily)was not initiated preoperatively, it
should be initiatedwithin6hours postoperatively and then continued
indefinitely to reduce the occurrence of saphenous vein graft closure
and adverse cardiovascular events.223,233,234 (Level of Evidence: A)
Class IIa
1. For patients undergoing coronary artery bypass grafting, clopidog-
rel 75 mg daily is a reasonable alternative in patients who are intol-
erant of or allergic to aspirin. (Level of Evidence: C)*Presence of established cardiovascular disease plus (1) multiple major risk factors
(especially diabetes), (2) severe and poorly controlled risk factors (especially con-
tinued cigarette smoking), (3) multiple risk factors of the metabolic syndrome
(especially high triglycerides 200 mg/dL plus non-high-density lipoprotein cho-
lesterol 130 mg/dL with low high-density lipoprotein cholesterol [<40 mg/dL]),
and (4) acute coronary syndromes.4.3. Management of Hyperlipidemia
Class I
1. All patients undergoing CABG should receive statin therapy, unless
contraindicated.235-247,247a (Level of Evidence: A)
2. In patients undergoing CABG, an adequate dose of statin should be
used to reduce low-density lipoprotein cholesterol to less than 100
mg/dL and to achieve at least a 30% lowering of low-density lipo-
protein cholesterol.235-239,247a (Level of Evidence: C)14 The Journal of Thoracic and Cardiovascular SurgeClass IIa
1. In patients undergoing CABG, it is reasonable to treat with statin
therapy to lower the low-density lipoprotein cholesterol to less
than 70 mg/dL in very high-risk* patients.236-238,247a,248-250 (Level
of Evidence: C)
2. For patients undergoing urgent or emergency CABG who are not
taking a statin, it is reasonable to initiate high-dose statin therapy
immediately.250a (Level of Evidence: C)
Class III: Harm
1. Discontinuation of statin or other dyslipidemic therapy is not rec-
ommended before or after CABG in patients without adverse reac-
tions to therapy.251-253 (Level of Evidence: B)4.4. Hormonal Manipulation
Class I
1. Use of continuous intravenous insulin to achieve and maintain an
early postoperative blood glucose concentration less than or equal
to 180 mg/dL while avoiding hypoglycemia is indicated to reduce
the incidence of adverse events, including deep sternal wound infec-
tion, after CABG.254-256 (Level of Evidence: B)
Class IIb
1. The use of continuous intravenous insulin designed to achieve a tar-
get intraoperative blood glucose concentration less than 140 mg/dL
has uncertain effectiveness.257-259 (Level of Evidence: B)
Class III: Harm
1. Postmenopausal hormonal therapy (estrogen/prosgesterone) should
not be administered to women undergoing CABG.260-262 (Level of
Evidence: B)4.5. Perioperative Beta Blockers
Class I
1. Beta blockers should be administered for at least 24 hours before
CABG to all patients without contraindications to reduce the
incidence or clinical sequelae of postoperative AF.263-267,267a-267c
(Level of Evidence: B)
2. Beta blockers should be reinstituted as soon as possible after CABG
in all patients without contraindications to reduce the incidence or
clinical sequelae of AF.263-267,267a-267c (Level of Evidence: B)
3. Beta blockers should beprescribed to all CABGpatientswithout con-
traindications at the time of hospital discharge. (Level of Evidence: C)
Class IIa
1. Preoperative use of beta blockers in patients without contraindi-
cations, particularly in those with an LV ejection fraction (LVEF)ry c January 2012
Hillis et al Clinical Guidelinegreater than 30%, can be effective in reducing the risk of in-
hospital mortality.268-270 (Level of Evidence: B)
2. Beta blockers can be effective in reducing the incidence of perioper-
ative myocardial ischemia.271-274 (Level of Evidence: B)
3. Intravenous administration of beta blockers in clinically stable
patients unable to take oral medications is reasonable in the early
postoperative period.275 (Level of Evidence: B)Class IIb
1. The effectiveness of preoperative beta blockers in reducing in-
hospital mortality rate in patients with LVEF less than 30% is
uncertain.268,276 (Level of Evidence: B)4.6. Angiotensin-Converting Enzyme Inhibitors and
Angiotensin-Receptor Blockers
Class I
1. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-
receptor blockers given before CABG should be reinstituted postoper-
ativelyonce the patient is stable, unless contraindicated.277-279 (Level of
Evidence: B)
2. ACE inhibitors or angiotensin-receptor blockers should be initiated
postoperatively and continued indefinitely in CABG patients who
were not receiving them preoperatively, who are stable, and who
have anLVEF less than or equal to 40%, hypertension, diabetesmel-
litus, or chronic kidney disease, unless contraindicated.278,279a,279b
(Level of Evidence: A)Class IIa
1. It is reasonable to initiate ACE inhibitors or angiotensin-receptor
blockers postoperatively and to continue them indefinitely in all
CABG patients who were not receiving them preoperatively and
are considered to be at low risk (ie, those with a normal LVEF in
whom cardiovascular risk factors are well controlled), unless con-
traindicated.278-282 (Level of Evidence: B)Class IIb
1. The safety of the preoperative administration of ACE inhibitors or
angiotensin-receptor blockers in patients on chronic therapy is un-
certain.283-288 (Level of Evidence: B)
2. The safety of initiating ACE inhibitors or angiotensin-receptor
blockers before hospital discharge is not well estab-
lished.278,280,282,289 (Level of Evidence: B)4.7. Smoking Cessation
Class I
1. All smokers should receive in-hospital educational counseling and
be offered smoking cessation therapy during CABG hospitaliza-
tion.291-293,293a (Level of Evidence: A)
Class IIb
1. The effectiveness of pharmacological therapy for smoking cessation
offered to patients before hospital discharge is uncertain. (Level of
Evidence: C)The Journal of Thoracic and C4.8. Emotional Dysfunction and Psychosocial
Considerations
Class IIa
1. Cognitive behavior therapy or collaborative care for patients with
clinical depression after CABG can be beneficial to reduce objective
measures of depression.294-298 (Level of Evidence: B)4.9. Cardiac Rehabilitation
Class I
1. Cardiac rehabilitation is recommended for all eligible patients after
CABG.299-301,301a-301d (Level of Evidence: A)4.10. Perioperative Monitoring
4.10.1. Electrocardiographic Monitoring
Class I
1. Continuous monitoring of the electrocardiogram for arrhythmias
should be performed for at least 48 hours in all patients after
CABG.265,302,303 (Level of Evidence: B)
Class IIa
1. Continuous ST-segment monitoring for detection of ischemia is rea-
sonable in the intraoperative period for patients undergoing
CABG.56,304-306 (Level of Evidence: B)
Class IIb
1. Continuous ST-segment monitoring for detection of ischemia
may be considered in the early postoperative period after
CABG.272,302,307-310 (Level of Evidence: B)
4.10.2. Pulmonary Artery Catheterization
Class I
1. Placement of a pulmonary artery catheter is indicated, pref-
erably before the induction of anesthesia or surgical incision,
in patients in cardiogenic shock undergoing CABG. (Level of
Evidence: C)
Class IIa
1. Placement of a pulmonary artery catheter can be useful in the intra-
operative or early postoperative period in patients with acute hemo-
dynamic instability.311-316 (Level of Evidence: B)
Class IIb
1. Placement of a pulmonary artery catheter may be reasonable in
clinically stable patients undergoing CABG after consideration of
baseline patient risk, the planned surgical procedure, and the prac-
tice setting.311-316 (Level of Evidence: B)
4.10.3. Central Nervous System Monitoring
Class IIb
1. The effectiveness of intraoperativemonitoring of the processed elec-
troencephalogram to reduce the possibility of adverse recall ofardiovascular Surgery c Volume 143, Number 1 15
Clinical Guideline Hillis et alclinical events or for detection of cerebral hypoperfusion in CABG
patients is uncertain.449-451 (Level of Evidence: B)
2. The effectiveness of routine use of intraoperative or early postoper-
ative monitoring of cerebral oxygen saturation via near-infrared
spectroscopy to detect cerebral hypoperfusion in patients undergo-
ing CABG is uncertain.317-319 (Level of Evidence: B)5. CABG-ASSOCIATED MORBIDITYAND
MORTALITY: OCCURRENCE AND PREVENTION:
RECOMMENDATIONS
5.1. Public Reporting of Cardiac Surgery Outcomes
Class I
1. Public reporting of cardiac surgery outcomes should use risk-
adjusted results based on clinical data.320-327 (Level of Evidence: B)
5.1.1. Use of Outcomes or Volume as CABG Quality
Measures
Class I
1. All cardiac surgery programs should participate in a state, regional,
or national clinical data registry and should receive periodic reports
of their risk-adjusted outcomes. (Level of Evidence: C)
Class IIa
1. When credible risk-adjusted outcomes data are not available, vol-
ume can be useful as a structural metric of CABG quality.328-342
(Level of Evidence: B)
Class IIb
1. Affiliation with a high-volume tertiary center might be considered
by cardiac surgery programs that perform fewer than 125 CABG
procedures annually. (Level of Evidence: C)5.2. Use of Epiaortic Ultrasound Imaging to Reduce
Stroke Rates
Class IIa
1. Routine epiaortic ultrasound scanning is reasonable to evaluate the
presence, location, and severity of plaque in the ascending aorta to
reduce the incidence of atheroembolic complications.343-345 (Level
of Evidence: B)5.3. The Role of Preoperative Carotid Artery
Noninvasive Screening in CABG Patients
Class I
1. A multidisciplinary team approach (consisting of a cardiologist,
cardiac surgeon, vascular surgeon, and neurologist) is recommen-
ded for patients with clinically significant carotid artery disease
for whom CABG is planned. (Level of Evidence: C)
Class IIa
1. Carotid artery duplex scanning is reasonable in selected patients
who are considered to have high-risk features (ie, age>65 years,16 The Journal of Thoracic and Cardiovascular Surgeleft main coronary stenosis, peripheral artery disease, history of
cerebrovascular disease [transient ischemic attack, stroke, etc.],
hypertension, smoking, and diabetes mellitus).346,347 (Level of
Evidence: C)
2. In the CABG patient with a previous transient ischemic attack
or stroke and a significant (50% to 99%) carotid artery steno-
sis, it is reasonable to consider carotid revascularization in con-
junction with CABG. In such an individual, the sequence and
timing (simultaneous or staged) of carotid intervention and
CABG should be determined by the patient’s relative magni-
tudes of cerebral and myocardial dysfunction. (Level of Evi-
dence: C)
Class IIb
1. In the patient scheduled to undergo CABG who has no history of
transient ischemic attack or stroke, carotid revascularization may
be considered in the presence of bilateral severe (70% to 99%)
carotid stenoses or a unilateral severe carotid stenosis with a contra-
lateral occlusion. (Level of Evidence: C)5.4. Mediastinitis/Perioperative Infection
Class I
1. Preoperative antibiotics should be administered to all patients to re-
duce the risk of postoperative infection.348-353 (Level of Evidence: A)
2. A first- or second-generation cephalosporin is recommended for
prophylaxis in patients withoutmethicillin-resistant Staphylococcus
aureus colonization.353-361 (Level of Evidence: A)
3. Vancomycin alone or in combination with other antibiotics to
achieve broader coverage is recommended for prophylaxis in
patients with proven or suspected methicillin-resistant S. aureus
colonization.356,362-364 (Level of Evidence: B)
4. A deep sternal wound infection should be treated with aggressive
surgical debridement in the absence of complicating circumstances.
Primary or secondary closure with muscle or omental flap is recom-
mended.365-367 Vacuum therapy in conjunction with early and
aggressive debridement is an effective adjunctive therapy.368-377
(Level of Evidence: B)
5. Use of a continuous intravenous insulin protocol to achieve and
maintain an early postoperative blood glucose concentration less
than or equal to 180mg/dLwhile avoiding hypoglycemia is indicated
to reduce the risk of deep sternalwound infection.256,259,378-381 (Level
of Evidence: B)
Class IIa
1. When blood transfusions are needed, leukocyte-filtered blood can
be useful to reduce the rate of overall perioperative infection and
in-hospital death.382-385 (Level of Evidence: B)
2. The use of intranasal mupirocin is reasonable in nasal carriers of
S. aureus.386,387 (Level of Evidence: A)
3. The routine use of intranasal mupirocin is reasonable in patients
who are not carriers of S. aureus, unless an allergy exists. (Level
of Evidence: C)
Class IIb
1. The use of bilateral internal mammary arteries in patients with
diabetes mellitus is associated with an increased risk of deep
sternal wound infection, but it may be reasonable when the
overall benefit to the patient outweighs this increased risk.
(Level of Evidence: C)ry c January 2012
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Class IIb
1. In patients with preoperative renal dysfunction (creatinine clear-
ance<60 mL/min), off-pump CABG may be reasonable to reduce
the risk of acute kidney injury.388-392 (Level of Evidence: B)
2. In patients with preexisting renal dysfunction undergoing on-
pump CABG, maintenance of a perioperative hematocrit greater
than 19% and mean arterial pressure greater than 60 mm Hg
may be reasonable. (Level of Evidence: C)
3. In patients with preexisting renal dysfunction, a delay of surgery af-
ter coronary angiography may be reasonable until the effect of ra-
diographic contrast material on renal function is assessed.393-395
(Level of Evidence: B)
4. The effectiveness of pharmacological agents to provide renal
protection during cardiac surgery is uncertain.396-418 (Level of
Evidence: B)5.6. Perioperative Myocardial Dysfunction
Class IIa
1. In the absence of severe, symptomatic aorto-iliac occlusive disease
or peripheral artery disease, the insertion of an intra-aortic balloon
is reasonable to reduce mortality rate in CABG patients who are
considered to be at high risk (eg, those who are undergoing reoper-
ation or have LVEF <30% or left main CAD).419-424 (Level of
Evidence: B)
2. Measurement of biomarkers of myonecrosis (eg, creatine kinase-
MB, troponin) is reasonable in the first 24 hours after CABG.425
(Level of Evidence: B)5.6.1. Transfusion
Class I
1. Aggressive attempts at blood conservation are indicated to limit he-
modilutional anemia and the need for intraoperative and periopera-
tive allogeneic red blood cell transfusion in CABG patients.426-429
(Level of Evidence: B)5.7. Perioperative Dysrhythmias
Class I
1. Beta blockers should be administered for at least 24 hours before
CABG to all patients without contraindications to reduce the inci-
dence or clinical sequelae of postoperative AF.263-267,267a-267c
(Level of Evidence: B)
2. Beta blockers should be reinstituted as soon as possible after CAB-
Gin all patients without contraindications to reduce the incidence or
clinical sequelae of AF.263-267,267a-267c (Level of Evidence: B)
Class IIa
1. Preoperative administration of amiodarone to reduce the incidence of
postoperative AF is reasonable for patients at high risk for postoper-
ative AFwho have contraindications to beta blockers.430 (Level of Ev-
idence: B)
2. Digoxin and nondihydropyridine calcium channel blockers can be
useful to control the ventricular rate in the setting of AF but are
not indicated for prophylaxis.265 (Level of Evidence: B)The Journal of Thoracic and C5.8. Perioperative Bleeding/Transfusion
Class I
1. Lysine analogues are useful intraoperatively and postopera-
tively in patients undergoing on-pump CABG to reduce perio-
perative blood loss and transfusion requirements.431-438 (Level
of Evidence: A)
2. A multimodal approach with transfusion algorithms, point-of-care
testing, and a focused blood conservation strategy should be used to
limit the number of transfusions.439-444 (Level of Evidence: A)
3. In patients taking thienopyridines (clopidogrel or prasugrel) or ti-
cagrelor in whom elective CABG is planned, clopidogrel and tica-
grelor should be withheld for at least 5 days224,225,227,228,445-451
(Level of Evidence: B) and prasugrel for at least 7 days 452 (Level
of Evidence: C) before surgery.
4. It is recommended that surgery be delayed after the administra-
tion of streptokinase, urokinase, and tissue-type plasminogen
activators until hemostatic capacity is restored, if possible. The
timing of recommended delay should be guided by the pharma-
codynamic half-life of the involved agent. (Level of Evidence: C)
5. Tirofiban or eptifibatide should be discontinued at least 2 to 4
hours before CABG and abciximab at least 12 hours before
CABG.230-232,436,437,453-457 (Level of Evidence: B)
Class IIa
1. It is reasonable to consider off-pump CABG to reduce periopera-
tive bleeding and allogeneic blood transfusion.458-464 (Level of
Evidence: A)6. SPECIFIC PATIENT SUBSETS:
RECOMMENDATIONS
6.1. Anomalous Coronary Arteries
Class I
1. Coronary revascularization should be performed in patients with:
a. A left main coronary artery that arises anomalously and then
courses between the aorta and pulmonary artery.465-467 (Level of
Evidence: B)
b. A right coronary artery that arises anomalously and then
courses between the aorta and pulmonary artery with evidence
of myocardial ischemia.465-468 (Level of Evidence: B)Class IIb
1. Coronary revascularization may be reasonable in patients with
a LAD coronary artery that arises anomalously and then
courses between the aorta and pulmonary artery. (Level of Ev-
idence: C)6.2. Patients With Chronic Obstructive Pulmonary
Disease/Respiratory Insufficiency
Class IIa
1. Preoperative intensive inspiratory muscle training is reasonable
to reduce the incidence of pulmonary complications in patients at
high risk for respiratory complications after CABG.469 (Level of
Evidence: B)ardiovascular Surgery c Volume 143, Number 1 17
Clinical Guideline Hillis et alClass IIb
1. After CABG, noninvasive positive pressure ventilation may be rea-
sonable to improve pulmonary mechanics and to reduce the need
for reintubation.470,471 (Level of Evidence: B)
2. High thoracic epidural analgesia may be considered to improve
lung function after CABG.472,473 (Level of Evidence: B6.3. Patients With End-Stage Renal Disease on
Dialysis
Class IIb
1. CABG to improve survival rate may be reasonable in patients with
end-stage renal disease undergoing CABG for left main coronary
artery stenosis of greater than or equal to 50%.474 (Level of Evi-
dence: C)
2. CABG to improve survival rate or to relieve angina despite GDMT
may be reasonable for patients with end-stage renal disease with sig-
nificant stenoses (70%) in 3 major vessels or in the proximal LAD
artery plus 1 other major vessel, regardless of LV systolic
function.475 (Level of Evidence: B)
Class III: Harm
1. CABG should not be performed in patients with end-stage renal dis-
ease whose life expectancy is limited by noncardiac issues. (Level of
Evidence: C)6.4. Patients With Concomitant Valvular Disease
Class I
1. Patients undergoing CABG who have at least moderate aortic ste-
nosis should have concomitant aortic valve replacement.476-479
(Level of Evidence: B)
2. Patients undergoing CABG who have severe ischemic mitral valve
regurgitation not likely to resolve with revascularization should
have concomitant mitral valve repair or replacement at the time
of CABG.480-485 (Level of Evidence: B)
Class IIa
1. In patients undergoing CABG who have moderate ischemic mitral
valve regurgitation not likely to resolve with revascularization, con-
comitant mitral valve repair or replacement at the time of CABG is
reasonable.480-485 (Level of Evidence: B)
Class IIb
1. Patients undergoing CABG who have mild aortic stenosis may be
considered for concomitant aortic valve replacement when evidence
(eg, moderate-severe leaflet calcification) suggests that progression
of the aortic stenosis may be rapid and the risk of the combined pro-
cedure is acceptable. (Level of Evidence: C)6.5. Patients With Previous Cardiac Surgery
Class IIa
1. In patients with a patent LIMA to the LAD artery and ischemia in
the distribution of the right or left circumflex coronary arteries, it is
reasonable to recommend reoperative CABG to treat angina if18 The Journal of Thoracic and Cardiovascular SurgeGDMT has failed and the coronary stenoses are not amenable to
PCI.186,486 (Level of Evidence: B)STAFF
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